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Abstract
Rationale TheN-methyl-D-aspartate (NMDA) receptor antag-
onists, including R-ketamine and rapastinel (formerly GLYX-
13), show rapid antidepressant effects in animal models of
depression.
Objective We compared the rapid and sustained antidepres-
sant effects of R-ketamine and rapastinel in the social defeat
stress model.
Results In the tail suspension and forced swimming tests,
R-ketamine (10 mg/kg, intraperitoneal (i.p.)) or rapastinel
(10 mg/kg, i.p.) significantly attenuated the increased im-
mobility time in the susceptible mice, compared with the
vehicle-treated group. In the sucrose preference test, both
compounds significantly enhanced the reduced preference
in susceptible mice 2, 4, or 7 days after a single injection.
All mice were sacrificed 8 days after a single injection.
Western blot analyses showed that R-ketamine, but not
rapastinel, significantly attenuated the reduced brain-derived
neurotrophic factor (BDNF)-TrkB signaling, postsynaptic
density protein 95 (PSD-95), and GluA1 (a subtype of α-ami-
no-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptor) in the prefrontal cortex, dentate gyrus, and CA3 of
the hippocampus in the susceptible mice. In contrast, both
compounds had no effect against the increased BDNF-TrkB
signaling, PSD-95, and GluA1 seen in the nucleus accumbens
of susceptible mice. Moreover, sustained antidepressant effect
of R-ketamine (3 mg/kg, intravenous (i.v.)), but not rapastinel
(3 mg/kg, i.v.), was detected 7 days after a single dose.
Conclusions These results highlight R-ketamine as a longer
lasting antidepressant compared with rapastinel in social de-
feat stress model. It is likely that synaptogenesis including
BDNF-TrkB signaling in the prefrontal cortex (PFC) and hip-
pocampusmay be required for the mechanisms promoting this
sustained antidepressant effect.
Keywords Antidepressant . Brain-derived neurotrophic
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Introduction
Depression is one of the most common psychiatric disor-
ders and the leading cause of disability worldwide.
Although antidepressants such as selective serotonin reup-
take inhibitors (SSRIs) and serotonin norepinephrine re-
uptake inhibitors (SNRIs) are generally effective in the
treatment of this disorder, it can still take weeks before
patients feel the full therapeutic benefits. Despite the effi-
cacy of standard treatments, approximately two-thirds of
patients with depression fail to respond to pharmacother-
apy. Therefore, the development of novel drugs capable of
inducing rapid and robust antidepressant responses in
treatment-resistant depressed patients is required (Chaki
and Fukumoto, 2015; Hashimoto 2015; Monteggia and
Zarate 2015).
The N-methyl-D-aspartate (NMDA) receptor antagonist
ketamine is one of the most attractive antidepressants for
treatment-resistant depression (Aan Het Rot et al. 2012;
Chaki and Fukumoto, 2015; Krystal et al. 2013;
Hashimoto 2009; Hashimoto et al. 2013; Lodge and
Mercier, 2015; Sanacora and Schatzberg 2015; Yang and
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Hashimoto 2014). A single sub-anesthet ic dose
(0.5 mg/kg) of ketamine produces a rapid and robust an-
tidepressant response in two-thirds of patients with
treatment-resistant depression, which can last for over a
week (Aan Het Rot et al. 2012; Berman et al. 2000;
Diazgranados et al. 2010; Zarate et al. 2006; 2012).
Ketamine is a racemic mixture containing equal parts of
R-ketamine and S-ketamine (esketamine). Esketamine has
an approximately fourfold greater affinity for the NMDA
receptor than the R-ketamine (Domino 2010). Singh et al.
(2016) reported that an infusion of esketamine caused a
rapid antidepressant effect in treatment-resistant depressed
patients, although psychotomimetic side effects were the
highest at 40 min after a single infusion. In contrast, R-
ketamine appears to be a potent, long-lasting, and safe
antidepressant, relative to esketamine, since R-ketamine
may appear to be free of side effects such as psychosis
and abuse liability (Hashimoto 2014, 2016a, 2016b; Yang
and Hashimoto 2014; Yang et al. 2015b, 2016; Zhang
et al. 2014). However, a clinical study of R-ketamine in
patients with depression has not yet been reported.
Rapastinel (formerly GLYX-13), a partial agonist at gly-
cine site of the NMDA receptor, shows antidepressant-like
effects without ketamine-like side effects in animal models
(Burgdorf et al. 2013; Moskal et al. 2014; 2016). A recent
double-blind, placebo-controlled study demonstrated that a
single intravenous (i.v.) infusion of rapastinel (5 or
10 mg/kg) produced rapid and sustained antidepressant ef-
fects in depressed patients who had not responded to an-
other antidepressant and that this drug did not elicit psy-
chotomimetic or other significant side effects (Preskorn
et al. 2015). Rapastinel was granted the Fast Track desig-
nation by the US FDA in 2014.
The purpose of this study was to compare the antidepres-
sant effects of R-ketamine and rapastinel in the social defeat
stress model of depression. In addition, we performedWestern
blot analysis of brain-derived neurotrophic factor (BDNF)-
TrkB pathway, postsynaptic density protein 95 (PSD-95),
and the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) receptor (GluA1), both of which are required
for synaptic plasticity in selected brain regions, since BDNF-
TrkB signaling and synaptogenesis are implicated in the
mechanisms of rapid antidepressant action of the NMDA re-
ceptor antagonists (Autry et al. 2011; Duman and Aghajanian
2012; Lepack et al. 2014; Ohgi et al. 2015; Yang et al. 2015b).
Materials and methods
Animals
Male adult C57BL/6 mice, aged 8 weeks (body weight
20–25 g, Japan SLC, Inc., Hamamatsu, Japan), and male
adult CD1 mice, aged 13–15 weeks (body weight >40 g,
Japan SLC, Inc., Hamamatsu, Japan), were used in exper-
iments. Animals were housed under controlled tempera-
tures and 12 h light/dark cycles (lights on between 07:00
and 19:00 h), with ad libitum food and water. This study
was carried out in strict accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol
was approved by the Chiba University Institutional
Animal Care and Use Committee. All efforts were made
to minimize suffering.
Drugs and drug administration
R-ketamine hydrochloride was prepared by recrystalliza-
tion of racemic ketamine (Ketalar®, ketamine hydrochlo-
ride, Daiichi Sankyo Pharmaceutical Ltd., Tokyo, Japan)
and D-(-)-tartaric acid (or L-(+)-tartaric acid), as described
previously (Zhang et al. 2014). The purity of these stereo-
isomers was determined by a high-performance liquid
chromatography (CHIRALPAK® IA; column size,
250 × 4.6 mm; mobile phase, n-hexane/dichloromethane/
diethylamine (75/25/0.1), Daicel Corporation, Tokyo,
Japan). On the day of intraperitoneal (i.p.) injection, ve-
hicle (10 ml/kg; distilled water), R-ketamine (10 mg/kg as
hydrochloride salt), and rapastinel (GLYX-13; 10 mg/kg,
Tocris Bioscience, Bristol, UK) were administered into
mice (Fig. 1a). The doses of R-ketamine (10 mg/kg) and
rapastinel (10 mg/kg) were selected as reported previously
(Lu et al. 2014; Yang et al. 2015b, 2016; Zhang et al.
2014). For i.v. administration experiment, vehicle (5 ml/
kg; distilled water), R-ketamine (3 mg/kg), and rapastinel
(3 mg/kg) were administered into mice (Fig. 1b). The
dose of rapastinel (3 mg/kg) was selected as reported pre-
viously (Burgdorf et al. 2013).
Social defeat procedure
The social defeat procedure was performed as previously
reported (Berton et al. 2006; Golden et al. 2011; Ren et al.
2016; Yang et al. 2015b; Zhang et al. 2015b). Every day,
the C57BL/6 mice were exposed to a different CD1 ag-
gressor mouse for 10 min, total for 10 days. When the
social defeat session ended, the resident CD1 mouse and
the intruder mouse were housed in one half of the cage
separated by a perforated Plexiglas divider to allow visu-
al, olfactory, and auditory contact for the remainder of the
24-h period. At 24 h after the last session, all mice were
housed individually. On day 11, a social interaction test
was performed to identify subgroups of mice that were
susceptible and unsusceptible to social defeat stress
(Fig. 1). This was accomplished by placing mice in an
interaction test box (42 × 42 cm) with an empty wire mesh
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cage (10 × 4.5 cm) located at one end. The movement of
the mice was tracked for 2.5 min, followed by 2.5 min in
the presence of an unfamiliar aggressor confined in the
wire mesh cage. The duration of the subject’s presence
in the “interaction zone” (defined as the 8-cm-wide area
surrounding the wire mesh cage) was recorded by a stop-
watch. The interaction ratio was calculated as time spent
in an interaction zone with an aggressor/time spent in an
interaction zone without an aggressor. An interaction ratio
of 1 was set as the cutoff: mice with scores <1 were
defined as “susceptible” to social defeat stress and those
with scores ≥1 were defined as “unsusceptible.” Only sus-
ceptible mice were used in the subsequent experiments.
Behavioral tests
Behavioral tests were performed as reported previously (Ren
et al. 2016; Yang et al. 2015b; Zhang et al. 2015b).
Locomotion The locomotor activity was measured by an
animal movement analysis system SCANETMV-40
(MELQUEST Co., Ltd., Toyama, Japan), and the mice
were placed in experimental cages (length × width ×
height, 560 × 560 × 330 mm). The cumulative exercise
was recorded for 60 min. Cages were cleaned between
testing session.
Tail suspension test (TST) A small piece of adhesive tape
placed approximately 2 cm from the tip of the tail for mouse.
A single hole was punched in the tape, and mice were hung
individually, on a hook. The immobility time was recorded for
10 min. Mice were considered immobile only when they hung
passively and completely motionless.
Forced swimming test (FST) The FST was tested by an
automated forced swim apparatus SCANET MV-40
(MELQUEST Co., Ltd., Toyama, Japan). The mice were
placed individually in a cylinder (diameter, 23 cm;
height, 31 cm) containing 15 cm of water, maintained
at 23 ± 1°C. Immobility time from activity time as
(total)–(active) time was calculated by the apparatus
analysis software. The immobility time for mouse was
recorded for 6 min.
Sucrose preference test (SPT)Mice were exposed to water
and 1 % sucrose solution for 48 h, followed by 4 h of water
Fig. 1 The schedule of social defeat stress, drug administration,
behavioral tests, and brain sampling. a Repeated social defeat stress
was performed for 10 days (day 1–day 10). Social interaction test was
performed on day 11, and susceptible mice were used in the subsequent
experiments. Vehicle (10 ml/kg, i.p.), R-ketamine (10 mg/kg, i.p.), or
rapastinel (10 mg/kg, i.p.) was administered (day 12). Locomotion test
(LMT) and tail suspension test (TST) were performed 2 and 4 h after a
single injection, respectively (day 12). Forced swimming test (FST) was
performed 1 day after injection (day 13). One percent sucrose preference
test (SPT) was performed 2 days (day 14), 4 days (day 15), and 7 days
(day 19) after injection. Collection of brain regions was performed at day
20. b Repeated social defeat stress was performed for 10 days (day 1–day
10). Social interaction test was performed on day 11, and susceptible mice
were used in the subsequent experiments. Vehicle (5 ml/kg, i.v.), R-
ketamine (3 mg/kg, i.v.), or rapastinel (3 mg/kg, i.v.) was administered
(day 12). LMTand TSTwere performed 2 and 4 h after a single injection,
respectively, (day 12). FSTwas performed 1 day after injection (day 13).
One percent SPT was performed 2 days (day 14), 4 days (day 15), and
7 days (day 19) after a single injection
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and food deprivation and a 1-h exposure to two identical
bottles, one is water and another is 1 % sucrose solution.
The bottles containing water and sucrose were weighed
before and at the end of this period, and the sucrose pref-
erence was determined.
Western blot analysis of proBDNF, BDNF, TrkB, p-TrkB,
PSD-95, and GluA1
Western blot analysis was performed as reported previously
(Yang et al. 2015b; Zhang et al. 2015b). Mice were sacrificed
and brains were rapidly removed from the skull.
Approximately 1-mm-thick coronal sections were cut, and
bilateral tissue punches of prefrontal cortex (PFC), nucleus
accumbens (NAc), CA1, CA3, and dentate gyrus (DG) of
the hippocampus were dissected on ice using a SZ-LED
Kenis light microscope (Osaka, Japan) and stored at −80 °C.
Basically, tissue samples were homogenized in Laemmli lysis
buffer. Aliquots (10 μg) of protein were measured using the
DC protein assay kit (Bio-Rad, Hercules, CA) and incubated
for 5 min at 95 °C, with an equal volume of 125 mMTris/HCl,
pH 6.8, 20 % glycerol, 0.1 % bromophenol blue, 10 % β-
mercaptoethanol, and 4 % sodium dodecyl sulfate, and sub-
jected to sodium dodecyl sulfate polyacrylamide gel electro-
phoresis, using 10 % mini-gels (Mini-PROTEAN® TGX™
Precast Gel; Bio-Rad, CA, USA). Proteins were transferred
onto polyvinylidene difluoride (PVDF) membranes using a
Trans Blot Mini Cell (Bio-Rad). For immunodetection, the
blots were blocked with 2 % BSA in TBST (TBS + 0.1 %
Tween-20) for 1 h at room temperature (RT) and kept with
primary antibodies overnight at 4 °C. The following primary
antibodies were used: BDNF (1: 200, Cat. no. H-117, Santa
Cruz Biotechnology, Inc., CA, USA), phosphor-TrkB (Tyr-
706) (1:200; Cat. no. sc135645, Santa Cruz Biotechnology),
TrkB (80E3) (1:1000; Cat. no. 4603, Cell Signaling
Technology), postsynaptic density protein 95 (PSD-95)
(1 μg/ml, Invitrogen, Carlsbad, CA, USA), and AMPA gluta-
mate receptor 1 (GluA1) (1 μg/ml, Abcam, Cambridge, MA,
USA). On the next day, blots were washed three times in
TBST and incubated with horseradish peroxidase-conjugated
anti-rabbit antibody (1:5000) 1 h, at RT. After final three
washes with TBST, bands were detected using enhanced
chemiluminescence (ECL) plus the Western Blotting
Detection system (GE Healthcare Bioscience). The blots then
were washed three times in TBST and incubated with the
primary antibody directed against β-actin. Images were cap-
tured with a Fuji LAS3000-mini imaging system (Fujifilm,
Tokyo, Japan), and immunoreactive bands were quantified.
Statistical analysis
The data are shown as mean ± standard error of the mean
(SEM). Analysis was performed using PASW Statistics 20
(formerly SPSS Statistics; SPSS). Comparisons between
groups were performed using the one-way analysis of vari-
ance (ANOVA), followed by post hoc Fisher’s least signifi-
cant difference (LSD) test. P values less than 0.05 were con-
sidered statistically significant.
Results
Effects of i.p. administration of R-ketamine and rapastinel
in the social defeat stress model
Ketamine produces rapid and long-lasting antidepressant ef-
fects in the chronic mild stress model and social defeat stress
model (Li et al. 2010; Ma et al. 2013; Yang et al. 2015b;
Zhang et al. 2015b). In this study, we compared the effects
of i.p. administration of R-ketamine and rapastinel in the so-
cial defeat stress model (Fig. 1a).
Locomotion showed no difference (F3, 32 = 0.727,
P = 0.543) among the four groups (Fig. 2a). In the TST and
FST, R-ketamine (10 mg/kg, i.p.) and rapastinel (10 mg/kg,
i.p.) significantly attenuated the increased immobility times in
susceptible mice (Fig. 2b, c). One-way ANOVA detected sta-
tistical significance in both the TST and FST (TST: F3,
32 = 9.839, P < 0.001; FST: F3, 32 = 15.547, P < 0.001) among
the four groups (Fig. 2b, c). In the SPT, preference of mice
after an injection of R-ketamine or rapastinel was significantly
higher (2D (day 14): F3, 32 = 8.851, P < 0.001, 2E (day 16):
F3, 32 = 15.236, P < 0.001, 2F (day 19): F3, 32 = 14.695,
P < 0.001) than that of the vehicle-treated group (Fig. 2d–f).
In the TST, FST, and SPT, efficacy of R-ketamine was more
potent than that of rapastinel. These behavioral data suggest
that i.p. administration of R-ketamine and rapastinel promote
rapid antidepressant effects in the social defeat stress model
and that R-ketamine produces longer lasting antidepressant
effects compared to rapastinel.
Levels of proBDNF and BDNF proteins in the brain
regions after i.p. administration of R-ketamine
or rapastinel
Since BDNF plays a role in the antidepressant action of keta-
mine (or R-ketamine) (Autry et al. 2011; Lepack et al. 2014;
Yang et al. 2015b), we performed Western blot analysis of
BDNF and its precursor, proBDNF, in selected brain regions
(PFC, NAc, DG, CA1, and CA3 of the hippocampus) 8 days
after a single dose of compound (Figs. 1a and 3). One-way
ANOVA of proBDNF data showed no significant changes in
any test group, for any brain region (Fig. 3a). One-way
ANOVA of BDNF data detected statistical significances in
all regions, except CA1 [PFC: F3, 20 = 5.524, P = 0.006;
NAc: F3, 20 = 3.118, P = 0.049; CA1: F3, 20 = 0.151,
P = 0.928; CA3: F3, 20 = 7.919, P = 0.001; DG: F3, 20 = 6.144,
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P = 0.004] (Fig. 3b). We found that social defeat stress signifi-
cantly decreased levels of BDNF protein in the PFC, DG, and
CA3, but not in CA1, while significantly increasing BDNF
protein in the NAc (Fig. 3b), consistent with previous data from
the social defeat stress model of depression (Ren et al.
2016; Yang et al. 2015b; Zhang et al. 2015b) and the rat
learned helplessness model (Shirayama et al. 2015; Yang
et al. 2015a). Interestingly, R-ketamine (10 mg/kg) significantly
attenuated reduced levels of BDNF protein in the PFC,
CA3, and DG 8 days after a single dose, although R-ketamine
did not affect the increased levels of BDNF protein in the NAc
(Fig. 3b). In contrast, rapastinel (10 mg/kg) did not affect
alterations in the BDNF levels in any region of susceptible
mice (Fig. 3b).
Levels of TrkB and p-TrkB proteins in the brain regions
after i.p. administration of R-ketamine or rapastinel
To clarify whether TrkB activation or inhibition underpins
mechanistic action of R-ketamine and rapastinel, we per-
formed Western blot analyses of TrkB and phosphorylated
TrkB (p-TrkB), an activated form of TrkB, in samples from
PFC, NAc, and CA1, CA3, and DG of hippocampus (Fig. 4).
One-way ANOVA of p-TrkB/TrkB ratio data showed
statistical significances in all regions, except CA1 [PFC: F3,
20 = 5.279, P = 0.008; NAc: F3, 20 = 7.665, P = 0.001; CA1: F3,
20 = 0.073, P = 0.974; CA3: F3, 20 = 7.791, P = 0.001; DG: F3,
20 = 5.424, P = 0.007] (Fig. 4a). Social defeat stress signifi-
cantly decreased levels of p-TrkB/TrkB ratio in the PFC,
DG, and CA3, but not in CA1, while significantly increasing
p-TrkB/TrkB ratio in the NAc (Fig. 4a), consistent with pre-
vious data from the social defeat stress model of depression
(Ren et al. 2016; Yang et al. 2015b; Zhang et al. 2015b).
Interestingly, R-ketamine (10 mg/kg) significantly attenuated
reduced levels of p-TrkB/TrkB ratio in the PFC, CA3, and DG
8 days after a single dose, although R-ketamine did not affect
the increased levels of the ratio in the NAc (Fig. 4a). In con
trast, rapastinel (10 mg/kg) did not affect alterations in the
ratio in any region of susceptible mice (Fig. 4a). One-way
ANOVA of TrkB protein data showed no significant changes
in any test group, for any brain region (Fig. 4b).
Levels of PSD-95 and GluA1 in selected mouse brain
regions after i.p. administration of R-ketamine
or rapastinel
We performed Western blot analysis on the synaptogene-
sis markers, PSD-95 and GluA1, in selected brain regions
Fig. 2 Effects of i.p. administration of R-ketamine and rapastinel in
social defeat stress model. a LMT (day 12), b TST (day 12), c FST
(day 13), d SPT (day 14), e SPT (day 16), and f SPT (day 19). The
values represent the mean ± SEM (n = 9 or 10). *P < 0.05, **P < 0.01,
***P < 0.001 compared with the vehicle-treated stress group. #P < 0.05,
##P < 0.01 compared with R-ketamine treated stress group. N.S. not
significant, Con control, Veh vehicle, R-Ket R-ketamine, Rap rapastinel,
LMT locomotion test, TST tail suspension test,FST forced swimming test,
SPT 1 % sucrose preference test
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(Fig. 5). One-way ANOVA of GluA1 data showed statis-
tical significances in all regions, except CA1 [PFC: F3,
20 = 3.941, P = 0.023; NAc: F3, 20 = 6.713, P = 0.003;
CA1: F3, 20 = 0.268, P = 0.848; CA3: F3, 20 = 5.071,
P = 0.009; DG: F3, 20 = 3.921, P = 0.024] (Fig. 5a). Eight
days after a single dose of test drug, social defeat stress
significantly decreased levels of GluA1 in the PFC, DG,
and CA3 of the hippocampus, but not CA1, whereas it
significantly increased the levels of GluA1 in the NAc
(Fig. 5a). Interestingly, R-ketamine significantly attenuat-
ed the reduction of GluA1 protein in the PFC, DG, and
CA3 after social defeat stress, although it had no effect on
the increased GluA1 levels in the NAc (Fig. 5a).
Furthermore, rapastinel did not affect alterations in
GluA1 levels following social defeat stress (Fig. 5a).
Next, we performed Western blot analysis of PSD95 in
selected mouse brain regions. One-way ANOVA of PSD-
95 data showed statistical significances in all regions, ex-
cept CA1 [PFC: F3, 20 = 6.992, P = 0.002; NAc: F3,
20 = 3.337, P = 0.040; CA1: F3, 20 = 1.004, P = 0.411;
CA3: F3, 20 = 7.922, P = 0.001; DG: F3, 20 = 8.229,
P = 0.001] (Fig. 5b). Eight days after a single dose of test
drug, social defeat stress significantly decreased levels of
PSD-95 in the PFC, DG, and CA3 of the hippocampus,
but not CA1, whereas it significantly increased the levels
of PSD-95 in the NAc (Fig. 5b). Interestingly, R-ketamine
significantly attenuated the reduction of PSD-95 protein
in the PFC, DG, and CA3 after social defeat stress, al-
though it had no effect on the increased PSD-95 levels in
the NAc (Fig. 5b). Furthermore, rapastinel did not affect
alterations in GluA1 levels in the brain regions following
social defeat stress (Fig. 5b).
Effects of i.v. administration of R-ketamine and rapastinel
in the social defeat stress model
In this study, we compared the effects of a single i.v. ad-
ministration of R-ketamine and rapastinel in the social de-
feat stress model of depression (Fig. 1b). Locomotion
showed no difference (F3, 32 = 0.014, P = 0.998) among
the four groups (Fig. 6a). In the TST and FST, R-ketamine
(3 mg/kg, i.v.) and rapastinel (3 mg/kg, i.v.) significantly
attenuated the increased immobility times in susceptible
mice (Fig. 6b, c). One-way ANOVA detected statistical
significance in both the TST and FST (TST: F3 ,
32 = 4.541, P = 0.009; FST: F3, 32 = 4.656, P = 0.008)
among the four groups (Fig. 6b, c). In the SPT, preference
of mice after i.v. injection of R-ketamine was significantly
higher (6D (day 14): F3, 32 = 9.422, P < 0.001, 6E (day 16):
F3, 32 = 6.829, P = 0.001, 6F (day 19): F3, 32 = 4.118,
Fig. 3 Levels of proBDNF and BDNF in the brain regions. a Western
blot analysis of proBDNF in PFC, NAc, CA1, CA3, and DG of the
hippocampus. The value was expressed as a percentage of that of
control mice. The values represent the mean ± SEM (n = 6 or 7). N.S.
not significant. bWestern blot analysis of BDNF (mature form) in PFC,
NAc, CA1, CA3, and DG of the hippocampus. The value was expressed
as a percentage of that of control mice. The values represent the mean
± SEM (n = 6 or 7). *P < 0.05, **P < 0.01, ***P < 0.001 compared with
the vehicle-treated stress group. #P < 0.05, ##P < 0.01 compared with R-
ketamine treated stress group. N.S. not significant. Con control, Veh
vehicle, R-Ket R-ketamine, Rap rapastinel
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P = 0.014) than that of the vehicle-treated group (Fig. 6d–
f). In the SPT (days 16 and 19), efficacy of R-ketamine was
significantly more potent than that of rapastinel (Fig. 6e, f).
These behavioral data suggest that a single i.v. injection of
R-ketamine and rapastinel promotes rapid antidepressant
effects in the social defeat stress model and that R-keta-
mine produces longer lasting antidepressant effects com-
pared to rapastinel.
Discussion
The major findings of this study are that a single dose (i.p.
and i.v.) of R-ketamine or rapastinel promoted a rapid
antidepressant response in the social defeat stress model
of depression and that R-ketamine produced longer lasting
antidepressant effects than rapastinel. The rapid and
sustained antidepressant effects of ketamine (or R-keta-
mine) in the social defeat stress model (Yang et al.
2015b; Zhang et al. 2015b; this study) are similar in time
course to the therapeutic effects seen in patients with
treatment-resistant depression and bipolar depression
(Aan Het Rot e t a l . 2012; Zara te e t a l . 2006;
Diazgranados et al. 2010; Zarate et al. 2012). To the best
of our knowledge, this is the first report showing a com-
parison of antidepressant effects for R-ketamine and
rapastinel in the social defeat stress model of depression.
We previously reported a marked reduction of BDNF
protein in the PFC, DG, and CA3, but not CA1, of
inflammation-induced depressed mice (Zhang et al.
2015a), social defeat stress model (Yang et al. 2015b;
Zhang et al. 2015b), and learned helplessness rats
(Shirayama et al. 2015; Yang et al. 2015a). In this study,
we found a marked reduction of BDNF protein in the
PFC, DG, and CA3, but not CA1, of susceptible mice
after social defeat stress. In contrast, we found that in-
flammation and learned helplessness induced a marked
increase in BDNF protein within the NAc (Zhang et al.
2015a; Yang et al. 2015a), consistent with higher BDNF
levels in the NAc of susceptible mice following social
defeat stress. The BDNF-TrkB pathway in the NAc plays
a role in the depression phenotype (Nestler and Carlezon
2006; Ren et al, 2015; Yang et al. 2015a; Zhang et al.
2015a; 2015b). In this study, we also found that social
defeat stress produced an opposing effect on BDNF pro-
tein levels in the PFC and hippocampus and NAc.
Previously, it was reported that intra-VTA BDNF injec-
tions lead to depression-like behavior, while a blockade of
Fig. 4 The ratio of p-TrkB/TrkB in the brain regions. a Western blot
analysis of TrkB and p-TrkB proteins in PFC, NAc, CA1, CA3, and
DG of the hippocampus. The value of p-TrkB/TrkB ratio was expressed
as a percentage of that of control mice. The values represent the mean
± SEM (n = 6 or 7). *P < 0.05, **P < 0.01, ***P < 0.001 compared with
the vehicle-treated stress group. #P < 0.05, ##P < 0.01 compared with R-
ketamine treated stress group. N.S. not significant. b The value of total
TrkB protein was expressed as a percentage of that of control mice.
Values represent the mean ± SEM (n = 6 or 7). N.S. not significant, Con
control, Veh vehicle, R-Ket R-ketamine, Rap rapastinel
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BDNF activity in the NAc produced antidepressant-like
effects (Nestler and Carlezon 2006). It is probable that
social defeat stress causes decreased BDNF in the hippo-
campus and PFC, but increased BDNF in the NAc,
resulting in depression-like behavior in mice.
We recently reported that TrkB agonist 7,8-DHF and
TrkB antagonist ANA-12 showed antidepressant activity
on inflammation (or social defeat stress)-induced depres-
sive behavior, by normalizing altered dendritic spines in
the PFC and hippocampus and NAc, respectively (Zhang
et al. 2015a; 2015b). Furthermore, we also found that
direct infusion of 7,8-DHF (but not ANA-12) into the
hippocampus (CA3 and DG) and PFC and of ANA-12
(but not 7,8-DHF) into the NAc promoted antidepressant
effects in the rat learned helplessness model (Shirayama
et al. 2015), implying that stimulation at TrkB in the PFC,
CA3, and DG, as well as blockade of TrkB in the NAc,
conferred antidepressant effects. Therefore, it is likely that
7,8-DHF and ANA-12 act by normalizing altered BDNF-
TrkB signaling in the PFC and hippocampus and NAc,
respectively. In this study, we found that R-ketamine
could attenuate reduced levels of BDNF protein in the
PFC, CA3, and DG, but not NAc, 8 days after a single
dose, consistent with previous reports (Yang et al. 2015b;
Zhang et al. 2015b). Therefore, it is unlikely that BDNF-
TrkB signaling in NAc is necessary to mediate the anti-
depressant effect of R-ketamine, although further studies
are needed.
In this study, a single dose of R-ketamine, but not
rapastinel, attenuated a marked increase levels of GluA1
(or PSD-95) proteins in the PFC, DG, and CA3, although
both drugs showed a rapid antidepressant effect in the
social defeat stress model. Considering the role of synap-
togenesis in the sustained antidepressant effect of keta-
mine (Duman and Aghajanian 2012; Ohgi et al. 2015),
it seems that long-lasting increases of GluA1 and PSD-
95 in the PFC, DG, and CA3 may underlie R-ketamine’s
long-lasting action. Nonetheless, further detailed studies
on the role of synaptogenesis in this sustained antidepres-
sant response are needed.
Burgdorf et al. (2013) reported that antidepressant effects
of rapastinel (3 mg/kg, i.v.) were similar to ketamine
(10 mg/kg, i.v.)-induced antidepressant effects in multiple rat
models of depression. In this study, we used the lower dose
Fig. 5 Levels of GluA1 and PSD-95 in the brain regions. aWestern blot
analysis of GluA1 in PFC, NAc, CA1, CA3, andDG of the hippocampus.
The value was expressed as a percentage of that of control mice. Values
represent the mean ± SEM (n = 6 or 7). *P < 0.05, **P < 0.01 compared
with the vehicle-treated stress group. N.S. not significant. bWestern blot
analysis of PSD-95 in PFC, NAc, CA1, CA3, and DG of the
hippocampus. The value was expressed as a percentage of that of
control mice. Values represent the mean ± SEM (n = 6 or 7). *P < 0.05,
**P < 0.01, ***P < 0.001 compared with the vehicle + stress group.
#P < 0.05, ##P < 0.01 compared with R-ketamine treated stress group.
N.S. not significant, Con control, Veh vehicle, R-Ket R-ketamine, Rap
rapastinel
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(3 mg/kg) of R-ketamine in the social defeat stress model.
It is noteworthy that R-ketamine (3 mg/kg, i.v.) has longer
lasting antidepressant effect than rapastinel (3 mg/kg, i.v.).
In addition, we also found that antidepressant effects of the
NMDA receptor antagonist MK-801 could not detected
7 days after a single dose although MK-801 showed rapid
antidepressant effect in the social defeat stress model
(Yang et al. submitted). Taken together, it is unlikely that
the NMDA receptor inhibition may play a key role in the
sustained antidepressant effects of ketamine.
The pharmacokinetic profile of ketamine in male C57/
B6 mice has been reported. The half-life of ketamine in
mouse plasma is approximately 30 min (Sato et al. 2004),
suggesting a possible rapid clearance of R-ketamine from
the body. To date, the pharmacokinetic profile of
rapastinel in mice is unknown. In this study, we detected
a sustained antidepressant response 7 days after a single
dose of R-ketamine or rapastinel although R-ketamine’s
sustained antidepressant effect was longer than that of
rapastinel. Taken together, it is unlikely that this differen-
tial antidepressant effect between R-ketamine and
rapastinel is due to differences in pharmacokinetic
profiles.
In conclusion, this study shows that a single dose of R-
ketamine or rapastinel can produce rapid antidepressant ef-
fects in the social defeat stress model of depression and that
R-ketamine elicits a longer lasting antidepressant effect than
rapastinel. Furthermore, it is likely that increased synaptogen-
esis in the PFC, DG, and CA3 of the hippocampus may be
involved in the sustained antidepressant response of R-
ketamine.
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